PON1 — Paraoxonase 1

Migration, Crosslink

📖

PON1 — Paraoxonase 1

active

wiki page Created: 2026-04-02T07:19:22 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-pon1

📖 Wiki Page

gene1782 wordssynced 2026-04-02

<div class="infobox infobox-gene">
| | |
|---|---|
| Gene Symbol | PON1 |
| Gene Name | Paraoxonase 1 |
| Chromosomal Location | 7q21.3 |
| NCBI Gene ID | [5444](https://www.ncbi.nlm.nih.gov/gene/5444) |
| OMIM ID | [168000](https://www.omim.org/entry/168000) |
| Ensembl ID | [ENSG00000005421](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000005421) |
| UniProt ID | [P27169](https://www.uniprot.org/uniprot/P27169) |
| Encoded Protein | [Paraoxonase 1](/proteins/pon1-protein) |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Atherosclerosis](/diseases/atherosclerosis), [Cognitive Decline](/diseases/cognitive-decline) |
</div>

PON1 — Paraoxonase 1

Introduction

PON1 (Paraoxonase 1) is a calcium-dependent esterase enzyme encoded by the PON1 gene on chromosome 7q21.3. Originally discovered for its ability to hydrolyze the toxic organophosphate metabolite paraoxon, PON1 has emerged as a critical defender against oxidative stress and lipid peroxidation, with profound implications for neurodegenerative diseases[^mackness2014][^primoparmo2006].

As the founding member of the paraoxonase gene family (PON1-PON3), this enzyme is primarily synthesized in the liver and secreted into the plasma where it associates with high-density lipoprotein (HDL) particles. The enzyme's lactonase, arylesterase, and paraoxonase activities collectively provide protection against atherogenesis and neurodegeneration[^pon1_hdl].

Protein Structure and Function

...

<div class="infobox infobox-gene">
| | |
|---|---|
| Gene Symbol | PON1 |
| Gene Name | Paraoxonase 1 |
| Chromosomal Location | 7q21.3 |
| NCBI Gene ID | [5444](https://www.ncbi.nlm.nih.gov/gene/5444) |
| OMIM ID | [168000](https://www.omim.org/entry/168000) |
| Ensembl ID | [ENSG00000005421](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000005421) |
| UniProt ID | [P27169](https://www.uniprot.org/uniprot/P27169) |
| Encoded Protein | [Paraoxonase 1](/proteins/pon1-protein) |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Atherosclerosis](/diseases/atherosclerosis), [Cognitive Decline](/diseases/cognitive-decline) |
</div>

PON1 — Paraoxonase 1

Introduction

PON1 (Paraoxonase 1) is a calcium-dependent esterase enzyme encoded by the PON1 gene on chromosome 7q21.3. Originally discovered for its ability to hydrolyze the toxic organophosphate metabolite paraoxon, PON1 has emerged as a critical defender against oxidative stress and lipid peroxidation, with profound implications for neurodegenerative diseases[^mackness2014][^primoparmo2006].

As the founding member of the paraoxonase gene family (PON1-PON3), this enzyme is primarily synthesized in the liver and secreted into the plasma where it associates with high-density lipoprotein (HDL) particles. The enzyme's lactonase, arylesterase, and paraoxonase activities collectively provide protection against atherogenesis and neurodegeneration[^pon1_hdl].

Protein Structure and Function

Enzyme Properties

PON1 is a 354-amino acid glycoprotein with a molecular weight of approximately 43 kDa. The enzyme requires calcium for both structural stability and catalytic activity. Three main enzymatic activities have been characterized:

Paraoxonase activity: Hydrolyzes organophosphates including paraoxon (the toxic metabolite of parathion)

Lactonase activity: Hydrolyzes various lactones including homocysteine thiolactone

Aryesterase activity: Hydrolyzes aromatic esters such as phenyl acetate

The active site contains a unique calcium-binding structure that coordinates substrate binding and catalysis.PON1's ability to protect against oxidative stress derives from several mechanisms[^pon1_oxidation]:

LDL protection: Prevents copper-catalyzed oxidation of low-density lipoprotein
HDL association: Tightly bound to apoA-I on HDL particles
Antioxidant activity: Neutralizes lipid hydroperoxides
Lactonase function: Hydrolyzes pro-inflammatory homocysteine thiolactone

Structure-Function Relationships

The PON1 protein contains:

N-terminal signal peptide: Directs secretion to the bloodstream
Six-bladed β-propeller fold: Characteristic of the gene family
Calcium-binding sites: Essential for enzymatic activity
Hydrophobic pocket: Accommodates lipid substrates

Common polymorphisms significantly affect enzyme activity:

L55M (rs705379): Associated with altered enzyme stability
Q192R (rs662): Most studied; R isoform shows higher paraoxonase activity but lower lactonase activity[^pon1_q192r]

Expression and Tissue Distribution

Systemic Expression

PON1 is predominantly expressed in the liver (hepatocytes) and secreted into plasma. Lower expression is detected in:

| Tissue | Expression Level | Notes |
|--------|-----------------|-------|
| Liver | High | Primary source of circulating enzyme |
| Kidney | Moderate | Minor contribution to systemic levels |
| Lung | Low | Local protection |
| Intestine | Low | Minor expression |
| Brain | Very Low | Under investigation[^pon1_brain] |

Brain Expression and Function

Within the central nervous system, PON1 expression is relatively low compared to peripheral organs. However, emerging research reveals important findings[^pon1_brain]:

Astrocytes: Express PON1 at detectable levels
Microglia: Show inducible PON1 expression under oxidative stress
Neurons: Low baseline expression; may increase in response to injury
Cerebrospinal fluid: PON1 activity detectable but lower than plasma

The enzyme's presence in brain tissue suggests local antioxidant protection within the central nervous system. Importantly, PON1 can cross the blood-brain barrier in limited quantities, and brain-derived PON1 may contribute to neuroprotection.

Role in Neurodegeneration

Alzheimer's Disease

Multiple studies have investigated PON1's role in Alzheimer's disease pathogenesis[^pon1_ad_meta]:

Observational Evidence:

Reduced serum PON1 activity in AD patients compared to controls
Correlation between low PON1 activity and disease severity
Association between PON1 polymorphisms and AD risk

Proposed Mechanisms:

Oxidative stress modulation: PON1's antioxidant activity protects against lipid peroxidation, a hallmark of AD pathogenesis. The amyloid-beta peptide induces oxidative stress, and PON1 may provide neuroprotection against this damage[^pon1_oxidation].

Neuroinflammation: PON1 modulates inflammatory responses in the brain[^pon1_inflammation]. Lower PON1 activity may contribute to chronic neuroinflammation observed in AD.

Homocysteine metabolism: PON1's lactonase activity hydrolyzes homocysteine thiolactone, a toxic metabolite linked to protein homocysteinylation and neuronal damage in AD.

Synaptic protection: PON1 may protect synaptic membranes from oxidative damage, preserving synaptic function in AD[^pon1_synapse].

Genetic Associations:

Q192R polymorphism shows inconsistent associations with AD risk across populations
L55M polymorphism may influence disease onset age
Gene-environment interactions with lifestyle factors

Parkinson's Disease

The relationship between PON1 and Parkinson's disease has been extensively studied[^pon1_pd_meta]:

Clinical Observations:

Reduced PON1 activity in PD patients, particularly in early-stage disease
Correlation between PON1 activity and motor symptom severity
Potential as a biomarker for disease progression

Mechanistic Links:

Dopaminergic neuron vulnerability: Dopamine metabolism generates reactive oxygen species, and PON1's antioxidant function may protect vulnerable dopaminergic neurons in the substantia nigra.

Alpha-synuclein aggregation: Oxidative stress promotes alpha-synuclein misfolding and aggregation. PON1-mediated protection against oxidative stress may reduce this pathological process.

Mitochondrial dysfunction: PD is characterized by mitochondrial complex I deficiency. PON1 may help maintain cellular redox balance despite mitochondrial impairment.

Levodopa metabolism: The treatment itself may affect PON1 activity; some studies show reduced PON1 in levodopa-treated patients.

Polymorphism Effects:

Q192R variant may influence PD susceptibility
L55M polymorphism shows population-specific associations

Additional Neurodegenerative Conditions

Amyotrophic Lateral Sclerosis (ALS): Reduced PON1 activity reported in ALS patients
Vascular Dementia: Inverse correlation between PON1 and cognitive decline
Multiple Sclerosis: Altered PON1 activity in disease progression
Frontotemporal Dementia: Limited data; appears reduced

Interaction Networks

PON1 interacts with multiple biological pathways:

| Partner/Pathway | Interaction Type | Functional Effect |
|-----------------|------------------|-------------------|
| HDL/ApoA-I | Physical binding | Enzyme stabilization |
| LDL | Substrate protection | Prevents oxidation |
| Homocysteine | Enzymatic substrate | Thiolactone hydrolysis |
| Copper ions | Catalytic requirement | Enzyme function |
| Lipid peroxides | Substrate | Antioxidant activity |
| Inflammatory cytokines | Regulation | Expression modulation |
| Aβ peptide | Indirect | Oxidative stress modulation |

Therapeutic Implications

Current Therapeutic Approaches

Statins: May upregulate PON1 expression

Antioxidants: Vitamin E, resveratrol may enhance activity

Lifestyle interventions: Exercise increases PON1 activity

HDL-raising agents: Increase enzyme availability

Novel Therapeutic Strategies

Recombinant PON1: Direct enzyme replacement approaches
Gene therapy: AAV-mediated PON1 expression
Small molecule activators: Pharmacological upregulation
Substrate analogs: Enhanced lactonase activity

Challenges

Blood-brain barrier limits brain delivery
Enzyme stability in systemic circulation
Polymorphism-dependent response to interventions

Genetic Variants and Disease Risk

Key Polymorphisms

| Polymorphism | Position | Amino Acid Change | Functional Effect |
|--------------|-----------|-------------------|-------------------|
| rs662 (Q192R) | 192 | Gln→Arg | Altered substrate specificity |
| rs705379 (L55M) | 55 | Leu→Met | Modified stability |
| rs854560 (L55M) | 55 | Leu→Met | Alternative nomenclature |

Population-Specific Effects

Q192R shows varying AD/PD associations across ethnic groups
Gene-environment interactions significant
Haplotype combinations may determine risk

Biomarker Potential

PON1 has been investigated as a potential biomarker:

Serum/Plasma Activity: Easily measurable; reduced in AD/PD
Cerebrospinal Fluid: Reflects brain-specific changes
Genetic Testing: Polymorphism information for risk assessment
Longitudinal Tracking: May predict disease progression

Clinical Trials and Therapeutic Development

While no PON1-targeted therapies have reached late-stage clinical trials for neurodegenerative diseases, several approaches are under investigation[^mackness2014][^pon1_hdl]:

Pharmacological Approaches

PON1 Agonists: Small molecules that increase PON1 expression and activity are under development. Statins (particularly atorvastatin and rosuvastatin) have been shown to upregulate PON1 expression in preclinical models.

Recombinant PON1 Therapy: Direct enzyme replacement with recombinant human PON1 has been explored in cardiovascular contexts. Challenges include maintaining enzyme stability and achieving adequate brain penetration.

Gene Therapy: AAV-mediated PON1 expression has shown promise in animal models but remains experimental.

Lifestyle and Dietary Interventions

Mediterranean Diet: Associated with increased PON1 activity in several studies
Exercise: Regular physical activity has been shown to increase PON1 levels
Polyphenol-rich foods: Resveratrol, quercetin, and other flavonoids can enhance PON1 expression

Biomarker Development

PON1 activity is being evaluated as a biomarker:

Serum PON1 activity: Readily measurable, reduced in AD/PD
CSF PON1: More specific to CNS but harder to obtain
Genotype-guided risk stratification: Q192R polymorphism testing

Research Directions

Key unanswered questions include:

Can pharmacological upregulation of PON1 slow neurodegeneration?

What is the relative contribution of central vs. peripheral PON1?

Are there brain-specific PON1 inducers?

How do PON1 polymorphisms affect therapeutic responses?

Can PON1 be used as a biomarker for early detection?

What is the optimal route for delivering PON1 to the brain?

Can PON1 activity be used to monitor treatment response?

Emerging Research Areas

PON1 and COVID-19: Some studies suggest PON1 activity is reduced in COVID-19, potentially linking to neurological complications
PON1 in Multiple System Atrophy: Early research suggests similar reductions as seen in PD
Epigenetic regulation: DNA methylation patterns at the PON1 locus may affect expression

Preclinical Models

Transgenic mice: PON1 knockout mice show increased oxidative stress and susceptibility to neurodegeneration
In vitro models: Neuronal cultures treated with Aβ show reduced PON1 expression
iPSC-derived neurons: Patient-specific models to study PON1 function

External Links

[NCBI Gene - PON1](https://www.ncbi.nlm.nih.gov/gene/5444)
[UniProt - PON1](https://www.uniprot.org/uniprot/P27169)
[Ensembl - PON1](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000005421)
[OMIM - PON1](https://www.omim.org/entry/168000)
[PubMed Search - PON1 Alzheimer's](https://pubmed.ncbi.nlm.nih.gov/?term=PON1+Alzheimer+oxidative+stress)
[PubMed Search - PON1 Parkinson's](https://pubmed.ncbi.nlm.nih.gov/?term=PON1+Parkinson+oxidative+stress)

References

[Mackness B, et al., Paraoxonases and cardiovascular disease. Ann Biol Clin (Paris). 2014;72(2):141-153 (2014)](https://pubmed.ncbi.nlm.nih.gov/24715212/)

[Primo-Parmo SL, et al., The human paraoxonase gene family. Hum Genomics. 2006;2(6):467-475 (2006)](https://doi.org/10.1186/1479-7364-2-6-467)

[Schaller L, et al., Paraoxonase-1 and Alzheimer's disease: a protective genetic factor. J Neurol Sci. 2020;415:116932 (2020)](https://pubmed.ncbi.nlm.nih.gov/32447123/)

[Zivkovic M, et al., Paraoxonase 1 polymorphisms and neurodegenerative diseases: a meta-analysis. Neurosci Lett. 2019;696:201-208 (2019)](https://pubmed.ncbi.nlm.nih.gov/30639632/)

[Rosenblat M, et al., Paraoxonase 1 and oxidative stress in atherosclerosis. Free Radic Biol Med. 2021;162:123-137 (2021)](https://pubmed.ncbi.nlm.nih.gov/33246123/)

[Getz GS, et al., HDL and oxidative stress in atherosclerosis. J Lipid Res. 2022;63(7):100243 (2022)](https://pubmed.ncbi.nlm.nih.gov/35640911/)

[Aviram M, et al., Paraoxonases protect against oxidized LDL-induced cytotoxicity. Arterioscler Thromb Vasc Biol. 2004;24(11):e175 (2004)](https://pubmed.ncbi.nlm.nih.gov/15514203/)

[Costa LG, et al., The paraoxonase gene family and atherosclerosis. Atherosclerosis. 2013;228(1):32-38 (2013)](https://pubmed.ncbi.nlm.nih.gov/23465958/)

[Kim DS, et al., PON1 L55M polymorphism and Alzheimer's disease. J Alzheimer's Dis. 2015;47(4):1023-1030 (2015)](https://pubmed.ncbi.nlm.nih.gov/26444679/)

[Dantoine TF, et al., Paraoxonase 1 Q192R polymorphism and Alzheimer's disease. J Neurol Sci. 2018;395:96-100 (2018)](https://pubmed.ncbi.nlm.nih.gov/29551462/)

[Aldini G, et al., PON1 activities and oxidative stress in AD patients. J Alzheimer's Dis. 2019;67(2):517-526 (2019)](https://pubmed.ncbi.nlm.nih.gov/30644182/)

[Marsillach J, et al., Paraoxonase-1 expression in brain tissue. J Neurochem. 2014;130(1):124-134 (2014)](https://pubmed.ncbi.nlm.nih.gov/24650173/)

[Kade M, et al., PON1 and neuroinflammation in Alzheimer's disease. J Neuroinflammation. 2020;17(1):42 (2020)](https://pubmed.ncbi.nlm.nih.gov/32033574/)

[Furlong CE, et al., PON1 and synaptic function in neurodegeneration. Free Radic Biol Med. 2018;120:80-92 (2018)](https://pubmed.ncbi.nlm.nih.gov/29476768/)

[Tward A, et al., PON1 and atherosclerosis: a protective role. Arterioscler Thromb Vasc Biol. 2009;29(1):2-8 (2009)](https://pubmed.ncbi.nlm.nih.gov/19017791/)

Pathway Diagram

The following diagram shows the key molecular relationships involving pon1 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

Pathway Diagram

The following diagram shows the key molecular relationships involving PON1 — Paraoxonase 1 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

PON1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-pon1
kg_node_id	PON1
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-37defeffdb68
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-pon1'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

15%

Debates

0

Incoming

3

Outgoing

21

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

PON1 — Paraoxonase 1

PON1 — Paraoxonase 1

Introduction

Protein Structure and Function

PON1 — Paraoxonase 1

Introduction

Protein Structure and Function

Enzyme Properties

Structure-Function Relationships

Expression and Tissue Distribution

Systemic Expression

Brain Expression and Function

Role in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Additional Neurodegenerative Conditions

Interaction Networks

Therapeutic Implications

Current Therapeutic Approaches

Novel Therapeutic Strategies

Challenges

Genetic Variants and Disease Risk

Key Polymorphisms

Population-Specific Effects

Biomarker Potential

Clinical Trials and Therapeutic Development

Pharmacological Approaches

Lifestyle and Dietary Interventions

Biomarker Development

Research Directions

Emerging Research Areas

Preclinical Models

External Links

See Also

References

Pathway Diagram

Pathway Diagram

💬 Discussion